Table 2.
Basic characteristics of the included studies
| Authors (year) | The route of administration | Groups (n): treatment (dose) | Duration of therapy | Follow-up time | Groups: age (mean ± SD) years | Prior surgery: percent of totals | Outcomes |
|---|---|---|---|---|---|---|---|
| AbdelHafeez [13] (2019) | Oral | Gabapentin (30): gabapentin (300–2700 mg) | 6 months | 3, 6 months | Gabapentin: (32.70 ± 4.91) years | Gabapentin: 16.67% |
(1) The change in pain scores from the baseline during the first 3 months of treatment (2) The change in pain scores from the baseline during the first 6 months of treatment (3) The proportion of patients reporting 30% or more reduction in pain score (4) The overall satisfaction rate (5) The incidence of dizziness, somnolence, and mood changes |
| Control (30): placebo | Control: (30.27 ± 5.32) years | Control: 6.67% | |||||
| Horne [3] (2020) | Oral | Gabapentin (153): gabapentin (300–2700 mg) | 16 weeks | 13–16 weeks | Gabapentin: (30.50 ± 7.70) years | No information |
(1) The change in pain scores from the baseline during the first 3 months of treatment (2) The BPI pain interference score (3) The proportion of patients reporting 30% or more reduction in pain score (4) The overall satisfaction rate (5) The incidence of dizziness, somnolence, and mood changes |
| Control (153): placebo | Control: (30.10 ± 8.60) years | ||||||
| Lewis [12] (2016) | Oral | Gabapentin (22): gabapentin (300–2700 mg) | 6 months | 3, 6 months | No information | No information |
(1) The change in pain scores from the baseline during the first 3 months of treatment (2) The change in pain scores from the baseline during the first 6 months of treatment (3) The BPI pain interference score (4) The total incidence of adverse events |
| Control (25): placebo | |||||||
| Sator-Katzenschlager [14] (2005) | Oral | Gabapentin (20): gabapentin (300–3600 mg) | 24 months | 1, 3, 6, 12, 24 months | Gabapentin: (40.40 ± 12.90) years | Gabapentin: 80.00% |
(1) The change in pain scores from the baseline during the first 3 months (2) The change in pain scores from the baseline during the first 6 months of treatment (3) The total incidence of adverse events |
| Control (20): amitriptyline (25–150 mg) | Amitriptyline: (36.70 ± 11.00) years | Amitriptyline: 80.00% |
n numbers, SD standard deviation, mg milligram, BPI Brief Pain Inventory